The FDA has approved Gilenya 0.5 mg daily, Novartis‘ first-line treatment for relapsing forms of multiple sclerosis. The FDA approval makes Gilenya the first oral treatment indicated for relapsing forms of MS available in the U.S. Gilenya reduces the frequency of MS relapses (flare-ups) and helps slow the build-up of some of the physical problems caused by MS. The approval was based on the largest clinical trial program ever submitted to date to the FDA for a new MS drug and included co...